These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38855174)

  • 1. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
    Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
    Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
    Plichta KA; Graves SA; Buatti JM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
    Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
    Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
    Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
    Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
    Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA-based therapeutics for prostate cancer.
    Stamatakos PV; Fragkoulis C; Leventi A; Gklinos K; Kontolatis N; Papatsoris A; Dellis A
    Expert Opin Pharmacother; 2024 Jul; 25(10):1405-1419. PubMed ID: 39054909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
    Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
    Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Ferdinandus J; Violet J; Sandhu S; Hofman MS
    Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
    Ilhan H; la Fougère C; Krause BJ
    Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
    Emmett L
    Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy.
    Oldan JD; Almaguel F; Voter AF; Duran A; Gafita A; Pomper MG; Hope TA; Rowe SP
    Cancer J; 2024 May-Jun 01; 30(3):176-184. PubMed ID: 38753752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.